Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. These data, together with the previously reported beneficial effect in colitis, suggest that TUDCA could be an add-on strategy to current immunosuppressive treatment of ulcerative colitis patients.
